Skip to main content
SpringerLink
Log in

How FABulous is PEGgy? Certoliziumab Pegol from the Bench to the Patients

  • Foreword
  • Published:
BioDrugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Acknowledgments

This article was published in a supplement sponsored by UCB Pharma SpA, Italy. The supplement was guest edited by Daniel Aletaha and peer reviewed by Leonard H. Calabrese who both received a small honorarium from Springer Healthcare to cover out-of-pocket expenses. D.A. has received honoraria and research grants from UCB, and honoraria from Abbvie, Grünenthal, Janssen, Merck, Medac, Mitsubishi Tanabe, Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk, and Sanofi/Regeneron. L.H.C. has consulted for UCB, Roche, Janssen, Pfizer and BMS.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria

    Daniel Aletaha

Authors
  1. Daniel Aletaha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Aletaha.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aletaha, D. How FABulous is PEGgy? Certoliziumab Pegol from the Bench to the Patients. BioDrugs 28 (Suppl 1), 3–4 (2014). https://doi.org/10.1007/s40259-013-0067-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40259-013-0067-9

Search

Navigation